Quick Answer
Oruka Therapeutics, Inc. reported Net Income Loss of -$105.43 million for the year ending 2025.
- Oruka Therapeutics, Inc. showed a decrease of -25.9% in Net Income Loss from 2024 to 2025.
- This data is from Oruka Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2004 to 2025 (22 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 22 years of available data (2004 to 2025), Oruka Therapeutics, Inc.'s Net Income Loss has declined by 20,532.7%.
- Historical annual values: Fiscal year 2025: -$105.43 million | Fiscal year 2024: -$83.72 million | Fiscal year 2023: -$5.34 million | Fiscal year 2022: -$9.93 million | Fiscal year 2021: -$19.32 million | Fiscal year 2020: -$9.74 million | Fiscal year 2019: -$5.48 million | Fiscal year 2018: -$7.93 million | Fiscal year 2017: -$18.49 million | Fiscal year 2016: -$16.44 million | Fiscal year 2015: -$11.45 million | Fiscal year 2014: -$9.69 million | Fiscal year 2013: -$6.94 million | Fiscal year 2012: -$4.32 million | Fiscal year 2011: -$5.36 million | Fiscal year 2010: -$8.42 million | Fiscal year 2009: -$9.14 million | Fiscal year 2008: -$19.43 million | Fiscal year 2007: -$13.99 million | Fiscal year 2006: -$5.24 million | Fiscal year 2005: -$1.46 million | Fiscal year 2004: -$511.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: